NCT05061992View on ClinicalTrials.gov

A Trial to Improve Quality of Life in People With Cirrhosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
Cirrhosis
Interventions
DRUG

Lactulose

"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT05061992 - A Trial to Improve Quality of Life in People With Cirrhosis | Biotech Hunter | Biotech Hunter